Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| AVADEL PHARMACEUTICALS | 12 | 6 | -0,55 % | ||
| HUTCHMED | 8 | 7 | -0,93 % | ||
| BIONTECH | 7 | 13 | +0,96 % | ||
| VIR BIOTECHNOLOGY | 6 | 2 | 0,00 % | ||
| INHIBRX BIOSCIENCES | 5 | - | 0,00 % | ||
| MONTE ROSA THERAPEUTICS | 4 | 21 | 0,00 % | ||
| NEUROCRINE BIOSCIENCES | 4 | 17 | -0,32 % | ||
| ALNYLAM PHARMACEUTICALS | 4 | 9 | -0,24 % | ||
| CYTOKINETICS | 4 | 1 | +0,94 % | ||
 | ALVOTECH | 4 | - | -1,40 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:13 | Compugen alters AstraZeneca deal to boost cash coffers | 5 | Globes | ||
| 15:00 | Alnylam To Expand Massachusetts Manufacturing Facility With $250 Million Investment | 79 | AFX News | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals (ALNY) on Wednesday said it plans to expand its manufacturing facility in Norton, Massachusetts, with an investment of about $250 million. The... ► Artikel lesen | |
| 14:59 | Alnylam To Expand Massachusetts Manufacturing Facility With $250 Million Investment | 2 | RTTNews | ||
| 14:55 | Hutchmed China kicks off clinical development of ATTC candidate | - | Alliance News | ||
| 14:50 | Bayer-Partner Cytokinetics: Nächste Top-News - folgt das Weihnachtsgeschenk? | 263 | Der Aktionär | Die Biotech-Gesellschaft Cytokinetics befindet sich in der heißen Zulassungsphase für seinen großen Hoffnungsträger Aficamten in den wichtigsten globalen Märkten. Während China grünes Licht erteilt... ► Artikel lesen | |
| 14:46 | RBC Kapital bestätigt "Outperform"-Rating für BeOne Medicines | 1 | Investing.com Deutsch | ||
| 14:46 | RBC Capital hebt Kursziel für Argenx auf 925 US-Dollar an | 2 | Investing.com Deutsch | ||
| 14:43 | Vanda Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald | 2 | Investing.com | ||
| 14:42 | BeOne Medicines stock rating reiterated at Outperform by RBC Capital | 2 | Investing.com | ||
| 14:42 | Argenx stock price target raised to $925 from $860 at RBC Capital | 3 | Investing.com | ||
| 14:36 | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | 137 | GlobeNewswire (Europe) | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| 14:30 | Alnylam to invest $250 million in expanding RNA drug manufacturing | 2 | Investing.com | ||
| 14:30 | Legend Biotech stock remains Overweight at Cantor Fitzgerald despite YTD decline | 1 | Investing.com | ||
| 14:22 | RNA-Spezialist Alnylam investiert 250 Millionen US-Dollar in Produktionsausbau | 6 | Investing.com Deutsch | ||
| 14:00 | Compugen rises on royalty deal with AstraZeneca | 3 | Seeking Alpha | ||
| 13:54 | Piper Sandler raises Arrowhead Pharma stock price target to $100 on Redemplo launch | 3 | Investing.com | ||
| 13:54 | China approves Cytokinetics' heart drug MYQORZO, triggering $7.5m payment | 2 | Investing.com | ||
| 13:54 | Acrivon to provide clinical data updates for cancer drugs in January | 1 | Investing.com | ||
| 13:50 | BIONTECH SE ADR wankt - jetzt den Moment erkennen! | 15 | Maximilian Berger | ||
| 13:46 | Amgen: Oppenheimer bestätigt "Outperform"-Rating mit Kursziel von 380 US-Dollar | 4 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .